Introduction
============

Infections due to pathogenic and opportunistic fungi are an ever increasing global health problem. Out of a total of about five million fungal species (spp.) worldwide, only 300 types are considered dangerous for humans, and 20--25 of these are able to affect humans on a frequent basis ([@B75]). The most common yeasts isolated during clinical practices are *Candida* spp. and *Cryptococcus* spp., while *Aspergillus* spp, is the most commonly isolated filamentous fungi. Other fungi like *Fusarium* spp., *Scedosporium* spp., *Penicillium* spp., and *Zygomycetes* are also identified as being the most life-threatening species for humans ([@B58]; [@B41]). The mortality rate for invasive candidiasis is about 40% ([@B4]), while the death rate for cryptococcosis varies from 20 to 30% ([@B7]) in wealthy countries with a fully functional health-care system. In countries where resources are limited, the death rate surpasses 50% ([@B71]). Instead, the mortality rate for invasive aspergillosis has diminished in the last 10 years, even if presently the plateau is steady at around 20% ([@B59]). Aggressive surgery, broad-spectrum antibiotics, prosthetic devices, grafts and general health-care associated infections increase the risk of invasive fungal infections ([@B25]). This latter type of infection by fungal species has reached 25% of all infections contracted in hospital conditions in the past two decades. In particular, systemic infections of *Candida* have risen steadily, reaching 8--15% of all human systemic infections ([@B26]; [@B24]; [@B40]; [@B83]).

The most widespread therapies for fungal infections are antifungal drugs, such as small molecules, monoclonal antibodies and radioimmunotherapy (RIT). At the beginning of the 2000s, RIT, a therapeutic strategy developed for cancer, was tested and tried out also for the treatment of fungal, bacterial, and viral infections, with considerable success ([@B14]). RIT employs the specificity of interaction between antigen and antibody to induce cytotoxicity in the target, by using radiolabeled monoclonal antibodies: this therapy was experimentally verified in the organs of mice infected systemically with *Cryptococcus neoformans* ([@B16]) and *Streptococcus pneumonia* ([@B15]). Over the past years antifungal treatments have concentrated above all on using the most common classes of small molecules and monoclonal antibodies directed against several fungal structures.

In this review, we describe both well-known and unexplored fungi molecular targets suitable for therapeutic intervention.

Fungal Structure: a Complex System
==================================

Fungi structure is very different to that of mammalian eukaryotic cells. Fungal walls are composed of matrix components embedded and linked to scaffolds of fibrous load-bearing polysaccharides.

Most of the major structural components of fungal pathogens are not found in humans, other mammals, or plants; for this reason, the immune system of animals and plants, that represents the first defense against pathogens, have evolved to recognize many of the conserved fungal components, and many antifungal drugs have been developed to inhibit the most representative and important target molecules of fungal structure ([@B32]).

Fungal species have a double protection from the outside world: an inner plasma membrane and an outer cell wall. Structurally, the plasma membrane is a phospholipidic bilayer similar to that of all eukaryotic organisms, while the composition can vary, due to the presence of specific fungal sterols that influence membrane fluidity, such as ergosterol, which also plays an important role in plasma membrane biogenesis and function. Ergosterol is essential for the activity and distribution of integral membrane proteins, and regulation of the cell cycle ([@B6]).

Deleting genes involved in the ergosterol biosynthesis is lethal to the fungi, showing that ergosterol is crucial for fungal cell viability ([@B2]). The plasma membrane is related to fungal virulence, because it is a dynamic structure that allows secretion of virulence factors, endocytosis, cell wall synthesis and invasive hyphal morphogenesis. The presence of integral membrane proteins is responsible for nutrient transport and pH sensing in the extracellular environment ([@B21]). On the basis of its specific function, the plasma membrane can be divided into domains of lipid and proteins ([@B60]; [@B88]). Several studies with *S. cerevisiae* reported that the fungal plasma membrane is organized in two domains: the most important one has been defined the Membrane Compartment of Pma1 (MCP) for the presence of the plasma membrane ATPase Pma1, and is involved in secretion and endocytosis; the other domain has been named the Membrane Compartment of Can1 (MCC) because it includes the arginine transporter Can1 ([@B35]; [@B57]; [@B73]; [@B67]; [@B20]). Two peripheral membrane proteins, Pil1 and Lsp1, bind the MCC at the cytoplasmic portion, forming a complex named eisosome, from the fusion of the two Greek terms "eis" (into or portal) and "soma" (body), because they were described as the sites of endocytosis ([@B101]). Successive studies have discredited this hypothesis, suggesting that MCC/eisosomes function as an area of plasma membrane which protects proteins against internalization: this is an essential regulatory mechanism, with regard to specific transporters, in order to ensure their stability in the membrane ([@B34]).

In addition to the plasma membrane, the most external envelope is the fungal cell wall, that constitutes the first defense against hostile environmental conditions. The dynamism of this structure is essential not only for cell viability and morphology, but also for fungal virulence; for this reason, the cell wall is the site of several signaling pathways which are activated, interacting with each other, under a finely regulated mechanism. The first evidence of the existence of signaling pathways at the cell wall was described in *Saccharomyces cerevisiae*, which resulted as a simple fungal model for molecular studies, due to its unicellular organization ([@B52]). In the last decades, different pathways have been identified as common and conserved across fungal species, such as mitogen activated protein kinases (MAPKs), calcineurin, cAMP, the target of rapamycin (Tor), and the entirety of these cascades is known as the Cell Wall Integrity pathway ([@B33]; [@B84]; [@B5]). All the stress signals received at the cell surface receptors are sent to the intracellular portion through downstream effectors that activate the production of cell wall components. The cell wall is generally organized as a scaffold of carbohydrate polymers to which a variety of proteins and other components are added, creating a strong but elastic structure ([@B32]). The polysaccharide composition can vary among the different species, but is characterized by conserved parts, such as a core of branched β-1,3-glucan-chitin ([@B98]). Chitin is produced as linear chains of β-1,4 *N*-acetylglucosamine and constitutes the most primordial structural polysaccharide in the fungal cell wall. Many families of enzymes with the role of chitin synthesis have been identified *in silico*, but the precise biochemical functions of many chitin synthase isoforms are unknown ([@B85]). A glucan synthase complex associated to the plasma membrane is responsible for the β-1,3 glucan synthesis: by using UDP-glucose as a substrate, linear β-1,3 glucan chains are extruded through the membrane into the cell wall for the subsequent transglycosylation ([@B19]). This protein complex is constituted by a Rho1 regulatory subunit and a Fks catalytic subunit, which is an integral plasma membrane protein with up to 16 *trans*-membrane helices. β-1,3 glucan chains are very abundant and important for cell wall maintenance and virulence function.

Synthetic Small Molecules: an Overview of Antifungal Drugs and Improvements
===========================================================================

Antifungal drugs currently used can be divided in four major classes, on the basis of their targets and mechanism of action ([Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}):

###### 

Current antifungal drugs described through their mechanism of action and biological effect.

  Antifungal drug family   Mechanism of action                                    Biological effect
  ------------------------ ------------------------------------------------------ -----------------------------------------------------------
  Polyenes                 Formation of pores in the fungal cell membrane         Increased membrane permeability accumulation of toxic ROS
  Pyrimidine analogs       Interfering with the fungal RNA and DNA metabolism     Impairment of the fungal RNA and DNA synthesis
  Azoles                   Inhibition of the fungal enzyme Erg11                  Block of the lanosterol to ergosterol conversion
  Echinocandins            Inhibition of the fungal enzyme β1,3-glucan synthase   Block of the cell wall β1,3-glucan synthesis

![Fungal cell and antifungal mechanism of action. Polyenes induce the formation of pores in fungal plasma membrane, with a consequent increased membrane permeability; azoles inhibit ERG11, the enzyme that converts lanosterol in 4,4-dimethylcholesta-8,14,24-trienol that can be subsequently converted to ergosterol, leading to lack of ergosterol and cell toxicity due to lanosterol accumulation; pyrimidine analogs are compounds incorporated into fungal RNA, that interfere with fungal RNA and DNA metabolism; echinocandins inhibit the β-1,3 glucan synthesis resulting in an increased chitin biosynthesis.](fphar-10-00080-g001){#F1}

1.  **polyenes**: amphotericin B is a small molecule and was the first antifungal drug approved. This drug acts by binding irreversibly to ergosterol-containing fungal membrane producing a channel that changes the membrane permeability with the emission of intracellular components^[1](#fn01){ref-type="fn"}^;

2.  **pyrimidine analogs**: flucytosine is a drug that through the cytosine permease is able to enter fungal cells, where it is converted into 5-fluorouracil by a cytosine deaminase. This latter compound is incorporated into fungal RNA, interfering with the RNA and DNA metabolism of fungi (see footnote 1);

3.  **azoles**: small molecules that belong to this family work by inhibiting the lanosterol 14α-demethylase (Erg11), the enzyme that converts lanosterol to ergosterol through forming the intermediate compound 4,4-dimethylcholesta-8,14,24-trienol, and consequently blocking ergosterol synthesis. From the first generation of azoles in the late 1970s, to the third one in the first decade of the 2000s, activity, safety, pharmacokinetics and new formulations have been improved.

4.  **echinocandins**: these antifungal drugs act by blocking the β (1,3)-[D]{.smallcaps}-glucan synthase, an enzyme that is essential for synthesis of β-1,3 glucan, a principal component of the cell wall of fungi that is not present in mammalian cells.

Fungal species have developed different mechanisms of resistance to antifungal drugs.

Resistance to amphotericin B is due to point mutations in the ergosterol biosynthetic pathway ([@B18]; [@B44]; [@B104]; [@B30]).

Mutations in the Fur1 gene (uracil phosphoribosyl transferase) and in the Fcy1 gene (cytosine deaminase), decrease conversion of the prodrug flucytosine into its active-toxic form 5-fluorouracil ([@B99]; [@B23]). The azoles family in *C. albicans*, reports three mechanisms of resistance: the reduction of azole accumulation through active efflux, the alteration or overexpression of the binding site (14α-sterol-demethylase, encoded by *ERG11*) and the loss-of-function downstream mutation in the ergosterol pathway (defective Δ-5,6-desaturase encoded by *ERG3*) ([@B44]; [@B47]). Echinocandins resistance has grown with the increasing use of these drugs in hospitals.

This resistance form is related to mutations in FKS1 which encodes the 1,3-β-[D]{.smallcaps}-glucan enzyme that concurs in the formation of the fungal cell wall. This mechanism has been most prominently observed in the haploid yeast, *C. glabrata*, and has recently been observed in mutations on MSH1 ([@B3]; [@B75]).

To overcome this hurdle, researchers have improved the present antifungal drugs and, on the basis of their categorization by type of compound, it is possible to focus on the different chemical modifications that can make antifungal drugs therapeutic also against fungal resistant strains:

1.  the improvements in **polyenes** are based on a modification in the drug structure that transforms the molecular-umbrella-conjugates to nanoparticles and polysaccharide-conjugates. The development of amphotericin B cochleate lipid-crystal nanoparticles as oral drug, showed *in vivo* activity and it is undergoing clinical trials (NCT02733432 and NCT02629419) ([@B17]);

2.  the improvements in **echinocandins** consider two different modifications: the first is based on a chemical change of the backbone to increase the stability, such as for CD101, whose clinical trials entered into phase II (NCT02733432 and NCT02734862) ([@B74]; [@B79]); the second concerns the 1,3-β glucan synthase inhibitor SCY078 (formerly MK-3118) developed by Scynexis and currently in phase II (NCT02679456). This specific drug is a triterpene and has an anti-yeast activity similar to echinocandins and, according to *in vitro* tests, is effective even against echinocandin-resistant yeasts ([@B100]);

3.  the improvements in **pyrimidine analogs** have produced a new compound, named F901318, that is able to inhibit the fungal dehydroorotate dehydrogenase, which is crucially involved in fungal pyrimidine biosynthesis ([@B72]; [@B22]);

4.  the improvements in **azoles** have been carried out by Viamet Pharmaceutical and are based on chemical modifications able to manipulate the metal-binding groups of azole compounds, reducing their interaction with cytochrome P450 and thus fewer potential drug-drug interactions. There are three new compounds:

    1.  VT-1161, now in phase II of clinical trials (NCT02267356 and NCT02267382) and developed to fight onychomycosis and vaginal candidiasis ([@B103]; [@B28]);

    2.  VT-1129, aimed toward cryptococcosis, worked exceptionally *in vitro* and in animal models;

    3.  VT-1598 is powerful and works against endemic mycosis and cryptococcosis ([@B55]).

Monoclonal Antibodies: New Biological Antifungal Drugs
======================================================

Monoclonal antibodies (mAbs) represent one of the most powerful therapeutic and diagnostic tools of modern medicine. Characteristics like specificity against antigens, high reproducibility and a high degree of purity has made these molecules extremely promising therapeutic agents in different clinic contexts such as cancer, infective and autoimmune diseases.

Upon immunization with the target antigen, transgenic mice produce specific human antibodies against the antigen and can be used to clone human antibodies with the conventional hybridoma technique. The advantage of this approach is the possibility to generate *in vivo* matured antibodies and the expression of full-length IgG. However, this specific method shows some disadvantages such as the use of murine-toxic antigens and the high similarity of the target antigen to its murine homologs. Since the 1990s, with the development of chimeric and humanized monoclonal antibodies, this drug class has been the most rapidly growing and advancing. Transgenic humanized mice provide an inestimable instrument for entirely human antibody production, and were created by replacing the mouse antibody gene with a human Ig loci ([@B56]). Recently, a new approach called CDR-grafting, generates improved humanized antibodies, which present a 85--90% content of human origins, and result less immunogenic than human-mouse chimeric ([@B13]).

During the last 8 years monoclonal antibody therapy in late stage clinical studies has increased from 20 newly produced antibodies to over 60, with a global market of US\$ 86 billion in 2016 and with an estimated increase over the next 4 years of US\$ 39 billion (\$125 billion) ([@B27]; [@B82]; [@B10]; [@B43]).

In the field of fungal infectious diseases, several mAbs have been produced ([Table 2](#T2){ref-type="table"}) and some examples are listed below.

###### 

Antifungal mAbs described through the pathogen and the specific antigen that are recognized.

  Antifungal mAbs   Source   Pathogen                                                                    Antigen
  ----------------- -------- --------------------------------------------------------------------------- ---------------------------------
  mAb C7            Mouse    *C. albicans, C. lusitaniae, C. neoformans, A. fumigatus, S. prolificans*   Cell wall mannoprotein
  mAb A9            Mouse    *A. fumigatus*                                                              Cell wall glycoprotein
  mAb 7B8 and 8G4   Mouse    *A. fumigatus* and *flavus*                                                 Galactomannan of *A. fumigatus*
  mAb 18B7          Mouse    *Cryptococcus* spp.                                                         Glucuronoxylomannan
  Mycograb          Human    *Candida* spp.                                                              Candida HSP(90)

MAb C7
------

In order to fight candidiasis, a monoclonal antibody directed against a *C. albicans* cell wall mannoprotein was developed, demonstrating its ability to inhibit fungal adhesion and germination, and indicating a direct candidacidal activity ([@B66]). Antibodies can reduce the adhesion of *C. albicans* to host surfaces by blocking the fungal cell wall adhesins ([@B86]) and also decreasing germination, another important activity involved in the adhesion mechanism ([@B45]). MAb C7 was tested in murine models of invasive candidiasis and demonstrated protection against *C. albicans* infection with both a longer mean survival time and a higher percentage of final survival ([@B90]). Further experiments have shown that mAb C7 was able to inhibit the growth of other fungal species, such as *Candida lusitaniae, Cryptococcus neoformans, A. fumigatus*, and *Scedosporium prolificans* ([@B66]). MAb C7 also exerted a candidacidal effect by impairing the iron uptake mechanism of *C. albicans*. In fact, all the fungal genes that showed deregulated expression after MAb C7 treatment were involved in iron uptake and homeostasis ([@B8]); furthermore, mAb C7 can also recognize Als3p, a hyphal-specific glycophosphatidylinositol cell wall protein that is responsible for interaction with host epithelial cells to acquire iron from their ferritin ([@B95]). All these data can explain the multiple action mechanisms of this monoclonal antibody.

MAb A9
------

During these same years, another monoclonal antibody was produced by using cell wall glycoprotein of *A. fumigatus* as antigen for mice immunization. MAb A9 was able to reduce hyphal development and the duration of spore germination, as demonstrated in proliferation *in vitro* assays. The efficacy of mAb A9 was also tested in murine models of invasive aspergillosis, showing the capacity to reduce fungal growth in specific organs, such as the kidney, and to increase the survival rate of treated animals compared to their negative controls ([@B12]).

MAbs 7B8 and 8G4
----------------

A very recent study reported novel murine mAbs that recognized *A. fumigatus* galactomannan. Mice were immunized with a synthetic pentasaccharide β-[D]{.smallcaps}-Gal*f*-(1,5)-\[β-[D]{.smallcaps}-Gal*f*-(1,5)\]~3~-α-[D]{.smallcaps}-Man*p*, structurally related to *A. fumigatus* galactomannan; two mAbs, 7B8 and 8G4, were selected for their effective affinity to the antigen of interest and were characterized, demonstrating a promising future diagnostic device to detect *A. fumigatus* galactomannan ([@B63]).

Mycograb
--------

Antibody-based therapies against fungal infections have been developed more and more in these last years, but most of them have been derived from mice. The generation of genetically engineered antibodies in a human configuration is a great innovation that allows also immunocompromised patients to respond to fungal infections, because the cooperation of immune system is not required for the antibodies to function. One of the first examples of a recombinant antibody was Mycograb^®^, a human monoclonal antibody against fungal heat shock protein 90 (HSP90). This protein has two ATP binding sites: when HSP90 binds ATP, a molecular conformational change occurs and Mycograb^®^might be responsible for the inhibition of HSP90 by blocking this change ([@B62]). *In vitro* and initial clinical data have demonstrated that Mycograb^®^is active against *Candida* spp. if used alone, but showed therapeutic synergism when combined with amphotericin B, fluconazole, and caspofungin ([@B9]). A therapeutic strategy based on the combination of drugs could increase the efficacy and eradicate the problem of antimicotic drug resistance.

MAb 18B7
--------

In the field of mycology, despite several monoclonal antibodies produced and tested for their efficacy against fungal species, there are very few examples of antibody-based therapies that have been studied clinically. Among these rare cases, a murine antibody against glucuronoxylomannan, a cryptococcal capsular polysaccharide, was produced and named mAb 18B7, tested *in vitro* and in animals, and then translated to a phase I dose-escalation study in HIV-infected patients who had been successfully treated for cryptococcal meningitis. Several doses of mAb 18B7 were used to establish the better treatment, but side effects were noticed and increased with the higher dose of administered drug: this led to defining the well tolerated dose that showed a pharmacological effect, demonstrated by a reduction in the serum cryptococcal antigen titers ([@B49]).

In addition to the improvement of classical antifungals, other drugs against new targets have been developed ([Table 3](#T3){ref-type="table"}). Further strategies still in development examine different antifungal drugs with the aim of using them both in therapeutic and in prophylactic therapy. Vaccines can be prophylactic for immunocompetent subjects who are going to start an immunosuppressive treatment, and therapeutic for already immunocompromised subjects ([@B69]; [@B94]).

###### 

New antifungal drugs.

  Antifungal drug   Mechanism of action
  ----------------- ---------------------------------------------------------------------------------------
  Aureobasidin A    Inhibition of inositol phosphoryl-ceramide (IPC) synthase ([@B1]; [@B65]; [@B50])
  APX001            Inhibition of glycosyl phosphatidylinositol (GPI) synthesis ([@B64]; [@B106]; [@B46])
  ASP2397           Disrupting the intracellular fungal biochemical machinery ([@B68])
  MGCD290           Inhibitor of HDAC (histone deacetylase) ([@B76], [@B80])
  FTY720            Modulator of sphingosine-1-phosphate receptor ([@B37])
  AR-12             Downregulation of host chaperones and inhibition of acetyl-CoA synthetase 1 ([@B48])
  Nikkomycines      Inhibition of chitin synthase ([@B38]; [@B93])

Immunotherapy based on factors stimulating the cytokine granulocitosis require further experimental studies, but some of them, such as GM-CSF, have already shown promising results and are in phase IV clinical trial ([@B102]).

Other possible antifungal drugs are those of antimicrobial peptides (AMPs) like VL-2397 and PAC-113, which are in phase II clinical trials. However, costs, toxicity, stability, and brief half-life are still the biggest unsolved issues ([@B70]).

MAb 2G8: a Successful Monoclonal Antibody Against β-1,3 Glucan of Pathogenic Fungi
==================================================================================

Targeting β-1,3 glucan can be useful in fighting fungal infections, and for this reason the idea of generating a vaccine based on this fungal cell wall component has been taken under consideration for several years. The concept of a unique vaccine for different fungal species is not achievable in practice, because the organization of β-glucans can vary amongst the organisms, determining a difference in the bonds of polysaccharidic structure, and all these dissimilarities result in a varying immunogenic capacity ([@B61]; [@B11]). However, β-glucan remains a significant antigen for vaccine development, as it becomes strongly immunogenic against numerous pathogenic fungi if conjugated to a protein carrier. The first glycol-conjugate vaccine ([@B96]) was generated by extracting laminarin, a β-1,3 glucan from the brown alga *Laminaria digitata*, in order to avoid contamination from other fungal antigens, such as mannoproteins; the low immunogenicity was solved by conjugating laminarin with the genetically detoxified diphtheria toxoid CRM197, a protein carrier already tested in other human vaccines ([@B31]; [@B39]). This vaccine, defined as Lam-CRM, was produced in various preparations and characterized by nuclear magnetic resonance for the integrity of the linked saccharide chains. Successively, it was verified to be protective against systemic candidiasis in mice and vaginal candidiasis in rats. These data indicated the possibility of developing an anti-β-glucan murine monoclonal antibody (mAb) to give passive protection against fungal infections; mAb 2G8 (IgG2b isotype) was generated and showed high affinity for β-1,3 glucan and protection against *Candida albicans* and *Aspergillus fumigatus* ([@B96]). In particular, *in vitro* experiments demonstrated the ability of Lam-CRM immune serum and mAb 2G8 to strongly inhibit growth of *C. albicans* and hyphal growth of *A. fumigatus*. MAb 2G8 showed its efficacy also *in vivo*: in a systemic mouse model of *Candida* infection, a single intraperitoneal administration of the mAb 2G8 2 h before an intravenous injection with the same fungal dose as the one used for testing passive protection by Lam-CRM immune serum conferred significant protection, (averaging a \>1-log decrease in the fungus kidney burden), compared to the control mice treated with an irrelevant anti-CRM mAb. In the same manner, in a rat model of vaginal candidiasis a single intravaginal administration of mAb 2G8 induced a more rapid fungus clearance, with the complete resolution of the infection after 21 days, compared to the control rats treated with an irrelevant anti-CRM mAb ([@B96]). The results of mAb 2G8 infusion were also verified on *Cryptococcus neoformans*, confirming their capability to bind and inhibit the growth and capsule formation of this fungal species *in vitro*, and demonstrating that mAb 2G8 decreased the size of the capsule in two encapsulated strains, both *in vitro* and *in vivo*. Furthermore, the anti-β-glucan mAb 2G8 induced the death of acapsular *C. neoformans* cells through opsonization, thus increasing the phagocytosis by human monocytes ([@B81]).

In a different study performed on *C. albicans*, mAb 2G8 was evaluated in comparison with a murine monoclonal antibody belonging to a different isotype, IgM, but showing the same Complementarity Determining Regions (CDRs) of both light and heavy chain: this antibody, named mAb 1E12, recognized oligosaccharides with β-1,3, β-1,4 and β-1,6 linkages, while mAb 2G8 was specific for β-1,3 glucan. In addition, mAb 2G8 showed significant protection in animal models of candidiasis, whereas mAb 1E12 was merely poorly protective and did not exert any fungal growth-inhibitory activity ([@B97]). This evaluation concluded that mAb 2G8 remarkably contrasted fungal virulence by specifically binding some β-glucan epitopes that play a crucial role in the cell wall assembly.

Novel Therapeutic Combination Strategy to Overcome Fungal Resistance
====================================================================

Antifungal resistance is an emerging problem in the treatment of fungal infectious diseases. Recent evidence has demonstrated that the percentage of resistant yeast strains has grown in the last years, due to a widespread use of common antifungal small molecules. Fluconazole is the most common and useful drug, since it presents reduced costs, is well-tolerated and allows oral administration. *Candida* spp., in particular non-*C. albicans* spp., that are responsible for many serious infections, are resistant to fluconazole and this substantially predisposes resistance to other azoles that share the same mechanism of action, inducing fungal defense strategies to impair the biological effect of this class of drugs. In different health care institutions and countries the rate of fluconazole resistance varies, from 12 to 18% for *C. glabrata* in the United States ([@B77]) reaching 50% in Chinese intensive care organizations also for *C. krusei, C. parapsilosis* and *C. tropicalis* ([@B36]; [@B53]; [@B107]). Echinocandins resistance is a less frequent mechanism and is mainly correlated to the antifungal treatment of each patient, with a directly proportional ratio between the time of exposure to echinocandins and the development of resistance against these compounds: there is clinical evidence of a 90% treatment failure rate in patients previously treated with echinocandins and infected by resistant strains of *C. glabrata*, successively isolated ([@B91], [@B92]). Very recently, an epidemiological study was conducted on 54 patients with *C. auris* infection from Pakistan, India, South Africa, and Venezuela during the years 2012--2015; through antifungal susceptibility testing and whole-genome sequencing it was demonstrated that 93% of isolates were resistant to fluconazole, 35% to amphotericin B, and 7% to echinocandins; 41% were resistant to 2 antifungal classes and 4% were resistant to three classes ([@B54]). These data are a confirmation of the relevance of growing resistance and the fungal ability to show multidrug resistance, making the choice of the correct therapy for each yeast infection a major clinical challenge. Regarding the resistance in *Aspergillus* spp., in addition to point mutations, the environmental exposure to azoles largely used in agriculture can increase the problem ([@B105]).

This evidence and knowledge signifies there is a need for novel medical approaches, new therapeutic strategies that take into account the fungal mechanisms of resistance, targeting specific molecules through different pathways/mechanisms. The choice of the molecular target is important for drug development, and β-glucans are a valid option, due to their abundance in the fungal cell wall of many yeasts spp. A novel class of glucan synthase inhibitors has recently taken on high relevance among antifungal drugs, they present the same mechanism of action exerted by echinocandins, but are structurally different.

MK-3118 (SCY-078) is a semi-synthetic derivative of the natural product enfumafungin, a potent inhibitor of fungal β-1,3-[D]{.smallcaps}-glucan synthases; chemically it is a triterpenoid and the great advantage is the oral bioavailability of this compound, an important step forward in antifungal drug administration methods, since most of the currently used drugs have only intravenous formulations. This compound is powerful because it is active against both wild-type and antifungal-resistant strains of *Aspergillus* spp.; a total of 71 *Aspergillus* strains were evaluated to establish the minimum effective concentration (MEC) endpoints for MK-3118 activity, because the mechanism of action based on inhibition of the fungal enzyme β-1,3 glucan synthase determines a reduced hyphal extension of *Aspergillus* spp. and not a complete growth arrest ([@B78]). MK-3118 was also tested against a collection of 135 selected clinical isolates representing the most clinically relevant non-*Aspergillus* fungal pathogens, including *Rhizopus* spp., *Mucor* spp., *Rhizomucor* spp., *Cunninghamella* spp., *Lichtheimia* spp. (previously *Absidia* spp.), *Fusarium* spp., *Scedosporium apiospermum*/*Pseudallescheria boydii* complex, *Scedosporium prolificans, Purpureocillium lilacinum* (previously *Paecilomyces lilacinus*), *Paecilomyces variotii*, and *Scopulariopsis* spp. In addition to the antifungal activity similar to that of echinocandins, MK-3118 was the only compound that showed activity against *S. prolificans* and *P. variotii*, for which there is a great lack of valid therapeutic possibilities ([@B87]). Through broth microdilution, antifungal carryover, and time-kill dynamics, the activity of MK-3118 was verified with positive results, against *C. albicans*, C. *parapsilosis, C. tropicalis* ([@B89]) and on many *fks*-mediated echinocandin-resistant strains, in particular those belonging to *C. albicans* and *C. glabrata* ([@B42]).

The efficacy of this novel antifungal drug was also investigated in a neutropenic murine model of invasive candidiasis, through a pharmacodynamic evaluation that showed very similar results to those for echinocandin intravenous formulations, even if the study presented a limited number of isolates utilized ([@B51]).

A very recent study analyzed the antifungal activity of MK-3118 in combination with other antifungal agents in the treatment of invasive aspergillosis: the synergistic effect of MK-3118 and amphotericin B was exerted both against wild-type and *cyp51* mutant *A. fumigatus* strains, suggesting that the combination of drugs could be particularly powerful in cases with a suspected azole resistance ([@B29]).

The combination of drugs could be the successful approach to fighting fungal infections, reducing the possibility of treatment failure due to an adaptive fungal response, very frequent principally in long-term therapies. Since β-1,3-[D]{.smallcaps}-glucan has been verified as an ideal molecular target for antifungal drugs, combining two agents that target this essential component of the fungal cell wall could be a novel and interesting therapeutic strategy. The hypothesis of investigating the synergistic antifungal effect of MK-3118 together with those well described for mAb 2G8 could be an innovative approach. The option to use a glucan synthase inhibitor along with a monoclonal antibody that directly inhibits β-1,3-[D]{.smallcaps}-glucan presents a dual mechanism with antifungal activity, which acts through different mechanisms to solve the problem of resistance development. In addition to the *in vitro* experiments performed to confirm antifungal activity of these two compounds, preclinical and clinical evaluations are necessary to validate this combination of drugs as a new antifungal treatment. In reference to the well-known ability of these agents to work singly, we expect a synergy in the combined functioning, to fight the most common fungal infections and ensure protection against resistance mechanisms.

Conclusion
==========

Despite the existence of a number of therapeutic opportunities, fungal infections remain amongst the diseases with the most urgent and widespread medical need. The underlying motivation is the limited success of antifungal drugs, which can be mostly attributed to delays in the diagnosis and detection of fungal infection. The present challenge is to identify targets for early diagnosis, to allow clinicians to treat patients as promptly as possible. The necessity for novel fungal molecular targets that can be directly recognized and strongly inhibited by new antifungal drugs, remains the crucial point for fungal infectious diseases. As concerns the improvement of currently used antifungal molecules, the method of administration, bioavailability and toxicity are good points for discussion, but the resistance of fungi strains continues to be the most serious problem connected to antifungal drug treatments. In closing, antifungal vaccines for the prevention of invasive fungal diseases may well be a good line of defense against the infections and the progression of related diseases, especially for patients with a high risk factor and the predisposition for this category of infectious diseases.
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